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Calcium Phosphate Crystals Induce Cell Death in Human
Vascular Smooth Muscle Cells
A Potential Mechanism in Atherosclerotic Plaque Destabilization
Alexandra E. Ewence, Martin Bootman, H. Llewelyn Roderick, Jeremy N. Skepper,
Geraldine McCarthy, Matthias Epple, Markus Neumann, Catherine M. Shanahan, Diane Proudfoot
Abstract—Vascular calcification is associated with an increased risk of myocardial infarction; however, the mechanisms
linking these 2 processes are unknown. Studies in macrophages have suggested that calcium phosphate crystals induce
the release of proinflammatory cytokines; however, no studies have been performed on the effects of calcium phosphate
crystals on vascular smooth muscle cell function. In the present study, we found that calcium phosphate crystals induced
cell death in human aortic vascular smooth muscle cells with their potency depending on their size and composition.
Calcium phosphate crystals of approximately 1 m or less in diameter caused rapid rises in intracellular calcium
concentration, an effect that was inhibited by the lysosomal proton pump inhibitor, bafilomycin A1. Bafilomycin A1
also blocked vascular smooth muscle cell death suggesting that crystal dissolution in lysosomes leads to an increase in
intracellular calcium levels and subsequent cell death. These studies give novel insights into the bioactivity of calcified
deposits and suggest that small calcium phosphate crystals could destabilize atherosclerotic plaques by initiating
inflammation and by causing vascular smooth muscle cell death. (Circ Res. 2008;103:e28-e34.)
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Vascular calcification is a common finding in aging, diabe-tes, chronic renal failure, and atherosclerosis. Although
calcium deposition is used as a diagnostic marker for atheroscle-
rosis and is associated with an increased risk of myocardial
infarction, its link with plaque rupture remains controversial.
Although some histological studies suggest that calcification
leads to plaque instability,1 other biomechanical studies demon-
strated no effect on plaque rupture.2 Indeed, it has been sug-
gested that a highly calcified fibrous cap may create a barrier that
protects plaque from rupture.3 Interestingly, investigations into
the size and distribution of calcified deposits in atherosclerotic
plaques have suggested that small, diffuse, “speckled,” or
“spotty” deposits cause local plaque stress and plaque instability,4–6
whereas large plate-like areas of calcification correlate with
stable plaques. Why these small calcific deposits should be
preferentially associated with plaque rupture is unknown.
Some clues as to the mechanisms involved in calcium
phosphate crystal-induced plaque instability come from studies
in synovial tissue, in which calcium phosphate crystals are
known to be damaging.7 The crystals are engulfed by fibroblasts
and a subsequent rise in intracellular calcium triggers a multitude
of downstream effects, including matrix metalloprotease produc-
tion. In macrophages, the crystals cause proinflammatory ef-
fects. Important studies in human monocyte/macrophages have
recently demonstrated that small, phagocytosable basic calcium
phosphate crystals were more potent in inducing the release of
tumor necrosis factor- compared with larger particles.8,9 These
studies suggested that microcalcific deposits in early stages of
atherosclerosis pose a greater inflammatory risk to the plaque
than macroscopically or radiologically visible deposits pres-
ent in more advanced lesions. However, these studies did not
address whether the different types of mineral present in the
plaque, which include hydroxyapatite, carbonated hydroxy-
apatite, and amorphous calcium phosphate have differential
effects on cell activation.10–12 Due to the protective role of
VSMCs in plaque rupture13 and the association of small
crystals with destabilized plaques, we aimed to determine
whether different types and sizes of calcium phosphate
crystals, including atherosclerotic vessel-derived crystals,
could affect VSMC function.
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Materials and Methods
Crystals and Particles
Crystals Extracted From Atherosclerotic Tissue
Crystals were prepared from samples of human carotid arteries
removed by endarterectomy from 3 different donors: a 61-year-old
man, a 64-year-old woman, and a 55-year-old man. The hardened,
obviously calcified regions were dissected from other areas of the
atherosclerotic vessels and digested with collagenase (3 mg/mL) and
elastase (1 mg/mL) overnight at 37°C. After digestion, the crystals
were washed 3 times in Hanks’ Balanced Salt Solution. Samples
were then placed on a 70-m sieve (Gibco) and washed further. The
remaining crystals (70 m) were crushed using a pestle and mortar
into Hanks’ Balanced Salt Solution, water, or serum-free M199.
Washing of the crystals at this stage was achieved using ultracen-
trifugation at 100 000 g to capture very small particles. For scanning
electron microscopy, samples were dusted onto spectroscopically
pure carbon disks attached to 13-mm Cambridge scanning electron
microscopy stubs and viewed uncoated in a FEI-Philips FEGSEM
operated at 5 kV. The transmission electron microscopy samples
were dusted onto holey carbon film grids (Agar Scientific) and
viewed in a FEI Philips CM100 transmission electron microscopy
operated at 100 kV. Images were recorded on Kodak 4489 cut film
and scanned as .tiff files using an AGFA Duoscan. Energy dispersive
x-ray microanalysis was performed as described previously.14
Basic Calcium Phosphate
Basic calcium phosphate (BCP) crystals were synthesized by alka-
line hydrolysis of brushite using previously described methods.15
Mineral prepared by this method has previously been shown to have
a calcium/phosphate molar ratio of 1.59 and contains partially
carbonate-substituted hydroxyapatite mixed with octacalcium phos-
phate as determined by Fourier transform infrared spectroscopy. The
crystals were weighed into vials and rendered pyrogen-free by
heating at 200°C for 90 minutes. Heating has previously been shown
not to alter the crystal character or the relationship of hydroxyapatite
or octacalcium phosphate as confirmed by x-ray diffraction and
Fourier transform infrared spectroscopy. Sonication gave crystal
sizes of approximately 1 m in diameter.
Nanoparticulate Apatite
Synthetic nanoparticulate particles were prepared as described
previously.16 These samples consisted of nanocrystalline-carbonated
apatite (Ca:PO43 molar ratio 1.57:1), nanocrystalline carbonated apatite
(Ca:PO43 molar ratio 1.39:1), nanocrystalline carbonate-free apatite
(Ca:PO43 molar ratio 1.34:1), and amorphous carbonate-free
apatite (Ca:PO43 molar ratio 1.23:1). These particles ranged from
100 to 300 nm in diameter.
Polystyrene latex beads (1 m diameter; Fluka 89904) were used
as a control particle.
All crystal preparations and beads were maintained under sterile
conditions and sonicated in serum-free medium199 before use.
Cell Culture
The culture medium used was M199 (Gibco) buffered with 3.7
mg/mL NaHCO3 and 5% CO2 and supplemented with 100 IU/mL
penicillin (Sigma), 100 mg/mL streptomycin, 250 ng/mL amphoter-
icin, and 4 mmol/L of L-glutamine (Sigma). Heat-inactivated fetal
calf serum (FCS) was purchased from Gibco. Human VSMCs were
obtained from nonatherosclerotic areas of aortas from organ donors
of various ages (both males and females, age ranged from 15 to 65
years). The cells were prepared from explants of the medial layer of
aortic tissue and were confirmed as smooth muscle cells by positive
staining with monoclonal antibodies against -smooth muscle actin
(A2547; Sigma). Cells were maintained in M199 medium containing
20% FCS and were used between passage 3 and 15.
Cell Viability Assay
Cell viability was measured by assessing mitochondrial activity of
VSMCs using an MTT kit (Sigma). VSMCs were plated in 96-well
plates at a density of 5000 cells/well in growth medium. After 16
hours, the medium was changed to 5% FCS/M199 with or without
crystals and the incubation continued for 72 hours. The MTT
solution (5 mg/mL MTT in RPMI-1640 without phenol red) was
added to the culture solution to a volume equal to 10%. Further
incubation at 37°C for 3 hours yielded purple MTT formazan
crystals. Once solubilized with MTT solvent (0.1 N HCl in anhy-
drous isopropanol; Sigma), the absorbance in each well was mea-
sured at 570 nm with the background (650 nm) subtracted.
Detection of Apoptosis
Time-lapse videomicroscopy was used to determine whether cells
exposed to crystals underwent apoptosis through the classical cell
membrane “blebbing” and subsequent cell fragmentation. VSMCs
were plated in 12-well dishes at 40 000 cells per well in growth
medium. After an overnight incubation at 37°C, the medium was
changed to 0.5% FCS/M199 with or without crystals gassed in 5%
CO2 for 30 minutes before being sealed. Images were captured
digitally every 10 minutes for 24 hours.
Additionally, VSMCs were plated in 4-well chamber slides,
10 000 cells per well in growth medium. After an overnight
incubation, the medium was changed to 0.5% FCS/M199 with or
without crystals. Crystals were incubated with VSMCs for up to 24
hours, washed in phosphate-buffered saline, fixed in 4%
formaldehyde/phosphate-buffered saline, and mounted in Mowiol
(containing DAPI). Apoptotic cells were identified by their bright,
condensed, punctuate, or fragmented nuclear morphology.
Proliferation Assay
VSMCs were plated in 24-well plates at a density of 10 000
cells/well in growth medium and allowed to attach overnight for 16
hours. The medium was then changed to 0.5% FCS/M199 to induce
quiescence. After 72 hours in 0.5% FCS, the medium was replaced
by 5% FCS/M199 with or without addition of crystals. Cells were
counted after trypsinization using a hemocytometer.
Measurement of Intracellular Calcium ([Ca2]i)
Measurement of cytosolic calcium was performed by monitoring
Fura-2 fluorescence of VSMCs adhered to glass coverslips using a
Perkin Elmer imaging system. Fura-2 was loaded into the cells by
incubation with 2 mol/L Fura-2 acetoxymethyl ester (30 minutes
incubation followed by a 30-minute period for de-esterification) in
physiological buffer (NaCl, 121 mmol/L; KCl, 5.4 mmol/L; MgCl2,
0.8 mmol/L; CaCl2, 1.8 mmol/L; NaHCO3, 6 mmol/L; D-glucose,
5.5 mmol/L; Hepes, 25 mmol/L; pH 7.3). A single glass coverslip
with adherent cells was mounted on the stage of a Nikon TE200
inverted epifluorescence microscope coupled to a xenon arc lamp
(Nikon) light source in a temperature-controlled chamber (37°C) and
sealed to eliminate evaporation after addition of agonists/crystals.
Fluorescence images were obtained with alternate excitation at 340
and 380 nm, which were selected using a Sutter filter wheel (Sutter
Industries). Emitted light was filtered at wavelengths 510 nm and
collected by a Hammamatsu Orca ER camera. The acquired images
were stored and subsequently processed offline with Ultraview
software (Perkin Elmer Life Sciences Ltd, Cambridge, UK).
The Fura-2/propidium iodide measurements were obtained using
an Olympus CellR imaging system configured around an Olympus
IX81 microscope. Cells were loaded with Fura-2 as described
previously and placed on the stage of the microscope. Propidium
iodide (0.5 g/mL) was added to the extracellular solution at the start
of the experiment. The cells were alternately excited at 340 nm (to
monitor calcium) and 490 nm (to monitor propidium iodide) with
emitted light being collected at 500 nm and 515 nm, respec-
tively. The fluorescence images were captured using a Hammamatsu
Orca ER camera. Analysis of changes in Fura-2 or propidium iodide
fluorescence was examined offline using ImageJ software.
In some experiments, bafilomycin A1 (10 nmol/L final concen-
tration; Sigma) was added to VSMCs 30 minutes before addition of
crystals. Bafilomycin A1 (10 nmol/L) was also present during
analysis.
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Statistics
Data shown are meansSD. Comparisons between 2 means were
performed using the Student t test.
Results
Analysis of Atherosclerotic Vessel-Derived Crystals
Electron microscopic and elemental analysis of human ath-
erosclerotic crystals showed that they consisted of calcium
phosphate and varied widely in size and morphology consis-
tent with other studies (Figure 1).10 The crystals ranged from
approximately 50 nm to 8 m. Although there was variation
in size, these crystals fall within the same size range as the
synthetic BCP (approximately 1 m diameter) and calcium
phosphate nanocrystals (ranging from 100 to 300 nm) pre-
pared for comparative studies (Figure 1).
Effects of Calcium Phosphate Crystals on Vascular
Smooth Muscle Cell Viability, Number,
and Apoptosis
VSMCs were treated with synthetic calcium phosphate crys-
tals and human atherosclerosis-derived crystals first to deter-
mine their effects on VSMC viability using an MTT assay.
BCP, human crystals, and each of the nanocrystalline parti-
cles (carbonated and noncarbonated apatite) significantly
reduced cell viability with amorphous carbonate-free apatite
having the greatest effect (Figure 2A). To confirm that the
effects seen were due to intact crystals, the crystals were
incubated in culture medium at 37°C for 24 hours, subjected
to ultracentrifugation, and the supernatant was added to
VSMCs. This crystal-conditioned medium (carbonate-free
apatite CM) did not reduce cell viability but caused a modest
significant increase in VSMC viability (Figure 2A). To
further confirm that cell death was not associated with crystal
dissolution in the culture medium, VSMCs were cultured in
media containing 3 times physiological calcium or up to 5
times the physiological level of phosphate in the presence of
serum and this had no effect on VSMC cell death as
previously described17 (data not shown).
Latex beads with 1 m diameter were used as a control
particle and had no effect on VSMC viability (Figure 2A).
Larger pieces of crystal (nonsonicated aggregates of40 m
diameter) had no effect on VSMC viability (Figure 2A),
suggesting that crystal size is important.
To determine if the reduction in cell viability was due to a
reduction in cell number, the effects on cell growth were
investigated by exposing synchronized VSMCs to BCP or
human crystals in the presence of 5% FCS over a 5-day
period and counting the number of VSMCs. In these exper-
iments, cell numbers were reduced in the presence of BCP
after 3 days of treatment (Figure 2B). However, the human
crystals had no effect at day 3 but significantly reduced
VSMC numbers after 5 days of treatment (Figure 2B). The
lack of effect of human crystals at day 3 was not due to effects
on proliferation of VSMCs because both BCP and human
crystals had minimal effects on proliferation as measured by
time-lapse videomicroscopy (data not shown). Therefore,
compared with BCP, human crystals were slower in causing
a reduction in cell numbers.
Using time-lapse videomicroscopy, apoptosis was signifi-
cantly increased in the presence of BCP (Figure 2C). BCP
and human crystals also significantly increased the numbers
of condensed or fragmented nuclei seen with DAPI staining,
indicative of increased VSMC apoptosis, with the human
crystals again being less potent than BCP (Figure 2D).
Effects of Crystals on Intracellular Calcium
([Ca2]i) Changes
Studies in synovial fibroblasts have suggested that the effects
of crystals on their proliferation are due to phagocytosis of
crystals, dissolution in lysosomes, and subsequent rises in
intracellular calcium [Ca2]i levels.18 Because changes in
[Ca2]i levels are also associated with induction of apoptosis,
we investigated whether the calcium phosphate crystals alter
VSMC [Ca2]i levels. We found that the addition of BCP
crystals to VSMCs caused a rapid rise in [Ca2]i (Figure 3A).
Figure 1. Crystal characteristics. A–B, Scanning electron
microscopy (SEM) images of crystals isolated from human
carotid atherosclerotic plaques. Crystal size ranged from
approximately 50 nm to 8 m (bar2 m for each image). C,
Transmission electron microscopy showing a cross-section of
atherosclerotic crystals (transmission electron microscopy,
bar200 nm). D, Electron dispersive x-ray spectroscopy (EDX)
of atherosclerotic crystals showing that they consist of mostly
calcium, phosphorous, and oxygen, consistent with an apatite-
like material. E, SEM image of BCP crystals with an average
particle size of 1 m (bar5 m). F, SEM image of nanocrystal-
line carbonated apatite (Ca:PO43 molar ratio 1.57:1) that ranged
in diameter from 100 to 300 nm (bar2 m).
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Figure 2. Effect of
crystals on VSMC
viability, proliferation,
and apoptosis. A,
VSMCs were
exposed to different
types of crystals
over 72 hours in 5%
FCS and VSMC
viability was mea-
sured using the
MTT assay. Each of
the crystal prepara-
tions was added at
150 g/mL (approxi-
mately 60 g/cm2)
and significantly
reduced cell viability
(P0.01 for each preparation compared with the control
containing no crystals, n4). BCP was partially carbonated
hydroxyapatite mixed with octacalcium phosphate, CAP1
was carbonated apatite (Ca:PO43 ratio 1.57:1), CAP2 was
carbonated apatite (Ca:PO43 ratio of 1.39:1), CFAP was
carbonate-free apatite (Ca:PO43 ratio of 1.34:1), and amor-
phous carbonate-free apatite was amorphous carbonate-free
apatite (Ca:PO43 ratio of 1.23:1). CFAP CM (conditioned
medium) caused a small, significant increase in cell viability
(P0.05, n4). Latex beads or nonsonicated, sieved crystals
(40 m) had no effect on cell viability (n4). B, Quiescent
VSMCs were stimulated to proliferate with 5% FCS M199
with or without BCP or human crystals (HC; 150 g/mL,
approximately 60 g/cm2). BCP reduced the number of cells
present after a 3-day treatment compared with controls
(P0.001, n3). HC significantly reduced cell numbers after
5 days (P0.005, n3). Fresh medium was replaced after 3
days of treatment. C, The number of cells undergoing apo-
ptosis was increased in the presence of BCP (5 g/mL,
approximately 2 g/cm2) as assessed by time-lapse videomi-
croscopy compared with controls containing no crystals (P0.01, n3). Inset, Arrow indicates a VSMC rounding up and fragmenting into apoptotic
bodies. D, BCP and human crystals increased numbers of VSMC condensed or fragmented nuclei using DAPI (inset image) with maximal effects
seen with the 150-g/mL dose (approximately 60 g/cm2; P0.01 for each concentration tested compared with controls, n4). Inset, Arrow indi-
cates a VSMC nucleus with a bright, condensed area suggesting this is an apoptotic cell.
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These responses occurred between 20 and 600 seconds after
addition of the crystals with each individual cell having its
own pattern of calcium signals. However, all cells displayed
one of 2 distinct responses to the crystals: (1) a sharp,
sustained rise (Figure 3A, cell 1); or (2) a sharp rise followed
by recovery to near baseline levels of calcium (Figure 3A,
cell 2). The cells that displayed sustained rises in calcium in
response to crystals rapidly lost Fura-2 dye, which was
accompanied by the simultaneous accumulation of propidium
iodide, indicating loss of membrane integrity (Figure 3E–F).
Importantly, latex beads did not alter [Ca2]i levels (Figure
3B) and the addition of extra calcium (3 times the physio-
logical level of calcium ions) did not affect [Ca2]i levels
(data not shown).
Figure 3. VSMC calcium
response to calcium phosphate
crystals. A, Representative
traces of [Ca2]i changes in
VSMCs stimulated with BCP
(150 g/mL, approximately 60
g/mL). Addition of BCP is
indicated by the arrow (at 600
seconds). Two distinct types of
responses to BCP were
observed, a sharp rise in [Ca2]i
that showed no recovery (as
for cell 1) or a sharp rise in
[Ca2]i followed by recovery to
baseline (cell 2). Cells that
showed no recovery to base-
line died (cell 1) as monitored
by loss of Fura-2 dye from the
cells. This image represents
data from an experiment in
which 21 cells were monitored,
11 of which went on to die. A
total of 91 cells in 8 separate
experiments displayed these
[Ca2]i patterns, 44 of which
died. B, Representative traces
of [Ca2]i changes in VSMCs
stimulated with amorphous cal-
cium phosphate (ACP) and
latex beads, both at a final
concentration of 150 g/mL,
approximately 60 g/cm2. ACP
induced either a sharp rise in
[Ca2]i followed by recovery to
baseline (cell 1, light gray line display-
ing cyclic transient changes in [Ca2]i)
or a sharp rise in [Ca2]i with no
recovery (cell 2, dark gray line). Latex
beads (black line) had no effects on
[Ca2]i. C, Representative traces of
the calcium response of 2 VSMCs
treated with BCP showing rises in
[Ca2]i that did not recover to base-
line. D, Representative traces of 2
equivalent VSMCs to those in C, pre-
treated with bafilomycin A1 (10 nmol/
L). In the presence of bafilomycin A1,
BCP caused small, oscillatory rises in
[Ca2]i. and all cells recovered to
baseline with no cell death compared
with approximately 50% cell death
induced with BCP alone in equivalent
cells. Bafilomycin A1 had no effect on
[Ca2]i when added alone. E, VSMCs
were loaded with Fura-2 and pro-
pidium iodide. i, The emission of
Fura-2 in one of the VSMCs that went
on to die, indicating a sudden loss of
dye at approximately 800 seconds. ii, The propidium iodide fluorescence in
the same cell and indicates a flux of propidium iodide into the cell that
coincides with Fura-2 loss. F, Phase-contrast images of the cells monitored
in E showing that at the start of the experiment, cells are clearly seen (i).
After 30 minutes of BCP addition, approximately half of these cells died and
cell debris accumulation is observed (ii). Bar10 m.
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Each of the different nanocrystalline preparations had
similar effects to BCP, ie, inducing [Ca2]i rises and cell death
accompanied by a loss of calcium homeostasis in approxi-
mately 50% of VSMCs and inducing transient cyclic in-
creases in [Ca2]i levels in the remaining 50% (Figure 3B). In
contrast, the human atherosclerotic crystals had little effect on
[Ca2]i levels over 1 hour of analysis (data not shown). We
hypothesized that like bone hydroxyapatite,19 human
atherosclerotic-derived crystals are associated with proteins,
including serum proteins, that may have the capacity to alter
crystal-induced calcium responses. To investigate this possi-
bility, we incubated BCP crystals in 1% FCS before addition
to VSMCs and found that they had no effect on [Ca2]i in
VSMCs (data not shown), suggesting that association of
calcium phosphate crystals with serum proteins can dampen
their activity.
The differential effects of calcium and crystals shown
previously suggested that the changes in [Ca2]i could be due
to crystal uptake and subsequent release of calcium ions after
acidification/dissolution of crystals in lysosomes. To test this,
we used bafilomycin A1, a specific inhibitor of lysosome
acidification. Bafilomycin A1 abolished the sharp rises in
[Ca2]i seen with BCP treatment of VSMCs (Figure 3C–D).
In the presence of bafilomycin A1, BCP failed to induce cell
death over 1 hour of analysis. These results suggested that
lysosomal degradation of calcium phosphate crystals was
necessary in causing increased [Ca2]i and mediating cell
death induced by the crystals.
Discussion
Apoptosis of plaque VSMCs has been linked with plaque
rupture and instability for some time.20 In the present study,
we have identified a novel mechanism for the induction of
VSMC death by calcium phosphate micro- and nanoparticles.
These observations may help to explain why microcalcifica-
tions have recently been found to cause local stress in
atherosclerotic fibrous caps6 and why speckled calcified
deposits are commonly found in ruptured coronary plaques.4
In addition to weakening of the fibrous cap, VSMC death
may have other downstream consequences within atheroscle-
rotic plaques, including potentiating further calcification by
providing a nidus for nucleation21 or potentially activating
various inflammatory pathways such as the release of cyto-
kines or other novel pathways such as release of HMGB122–24
with further studies now required to further explore these
downstream effects.
Calcium phosphate crystals have been shown to have
activity in cell types other than VSMCs. For example,
hydroxyapatite-containing “atherosclerotic gruel”-induced
apoptosis in macrophages,25 and calcium phosphate nanoc-
rystals have been reported to induce apoptosis in cancer
cells.26 In synovial fibroblasts, proliferation is enhanced in
the presence of calcium phosphate crystals,7 which implies
that there is some cell specificity in the response of a cell to
calcium phosphate crystals. Experiments investigating the
[Ca2]i response in VSMCs revealed that calcium phosphate
crystals caused rapid rises in [Ca2]i in all of the cells
analyzed. In approximately 50% of the cells, the [Ca2]i rises
did not recover back to baseline and these cells died. Why
only 50% of the cells responded in this way is intriguing.
Because of the heterogeneous nature of VSMCs, it is possible
that one population of VSMCs within each isolate has
different calcium handling mechanisms, phagocytosis kinet-
ics, or susceptibility to cell death. Experiments using bafilo-
mycin A1 showed that inhibition of lysosomal proton pump
activity reduced the magnitude of [Ca2]i rises and inhibited
cell death induced by BCP. This suggests that calcium
phosphate crystals are rapidly degraded in lysosomes and
subsequent acidification leads to the release of calcium into
the cell. We expect that the released calcium is initially
sequestered by calcium stores or pumped out of the cell until
the sustained calcium rise leads to loss of function of
membrane pumps leading to cell death. The mechanism of
intracellular mobilization of calcium from the lysosomes is
currently unknown and could involve a number of pathways,
including nicotinic acid adenine dinucleotide phosphate.27
Further studies are required to elucidate the exact mecha-
nisms involved in the crystal-induced [Ca2]i rise and subse-
quent cell death.
Scanning electron microscopy demonstrated that calcified
extracts from atherosclerotic tissue contained calcium phos-
phate crystals of different shapes and sizes, which is in
agreement with other studies.10 We did not detect carbonated
forms of crystals in our samples as seen in other studies and
in our own previous in vitro studies of calcified VSMC
apoptotic bodies.21 However, synthetic carbonated or noncar-
bonated forms of hydroxyapatite had similar effects in reduc-
ing VSMC viability. The nanocrystals (300 nm) and BCP
(approximately 1 m) had similar effects in reducing cell
viability; however, aggregates of greater than 40 m did not
reduce cell viability. This is likely to be due to a lack of
phagocytosis of larger particles and implies that small non-
aggregated particles in atherosclerotic plaques may be more
cytotoxic to VSMCs compared with larger deposits. These
observations complement studies in macrophages in which
crystals of 1 to 2 m diameter were more potent than larger
crystals (approximately 15 m) in causing the release of
proinflammatory cytokines.9
The crystal preparation with the greatest effect in reducing
cell viability was amorphous calcium phosphate, which raises
the possibility that the active regulation of calcification is
designed to produce crystals similar to hydroxyapatite found
in blood vessels and bone, because these are less damaging
than more soluble forms of calcium phosphate. In support of
this, crystals isolated from atherosclerotic tissue were less
potent than synthetic crystal preparations at reducing cell
viability, they were slower in reducing cell numbers, and they
had little effect on calcium levels in VSMCs. The reduced
potency of the human crystals may be due to having different
surface properties and containing factors such as antiapoptot-
ic and calcification-regulatory proteins (including fetuin) that
may offset their detrimental effects. In support of this, in
contrast to untreated BCP crystals, serum-treated BCP crys-
tals had no effect on calcium levels in VSMCs. Indeed,
VSMCs in vivo will not be exposed to pure, uncoated crystals
but will meet them in the context of their associated factors
and microenvironment within the plaque that may alter the
kinetics of crystal phagocytosis and toxicity.
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If as our study suggests, the degree of potency of crystals
in inducing VSMC death is dependent on their size, compo-
sition, and associated factors, this will have important impli-
cations for how we design treatments to ameliorate plaque
calcification.
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